See the DrugPatentWatch profile for keytruda

Comparing the Cost of Keytruda to its Competitors: A Comprehensive Analysis

Introduction

Keytruda, a medication developed by Merck & Co., has revolutionized the treatment of various types of cancer, including melanoma, lung cancer, and head and neck cancer. Its success has led to increased competition in the market, with other pharmaceutical companies developing similar treatments. One of the most pressing concerns for patients and healthcare providers is the cost of these medications. In this article, we will explore how the cost of Keytruda compares to its competitors.

What is Keytruda?

Keytruda, also known as pembrolizumab, is a monoclonal antibody that works by blocking the interaction between PD-1 and PD-L1, two proteins that help cancer cells evade the immune system. This allows the immune system to recognize and attack cancer cells more effectively.

Cost of Keytruda

According to the Merck & Co. website, the wholesale acquisition cost (WAC) of Keytruda is around $12,500 per month. However, the actual cost to patients and healthcare providers can vary depending on several factors, including the patient's insurance coverage, the dosage, and the administration method.

Cost of Competitors

Several pharmaceutical companies have developed similar treatments to Keytruda, including:

* Opdivo (nivolumab): Developed by Bristol-Myers Squibb, Opdivo is a PD-1 inhibitor that has been approved for the treatment of various types of cancer, including melanoma, lung cancer, and kidney cancer. The WAC of Opdivo is around $12,000 per month.
* Yervoy (ipilimumab): Developed by Bristol-Myers Squibb, Yervoy is an immunotherapy medication that works by stimulating the immune system to attack cancer cells. The WAC of Yervoy is around $10,000 per month.
* Tecentriq (atezolizumab): Developed by Genentech, Tecentriq is a PD-L1 inhibitor that has been approved for the treatment of various types of cancer, including lung cancer and urothelial carcinoma. The WAC of Tecentriq is around $12,000 per month.

Comparison of Costs

As shown in the table below, the cost of Keytruda is slightly higher than its competitors. However, it's essential to note that the actual cost to patients and healthcare providers can vary depending on several factors.

| Medication | Wholesale Acquisition Cost (WAC) | Monthly Cost |
| --- | --- | --- |
| Keytruda (pembrolizumab) | $12,500 | $12,500 |
| Opdivo (nivolumab) | $12,000 | $12,000 |
| Yervoy (ipilimumab) | $10,000 | $10,000 |
| Tecentriq (atezolizumab) | $12,000 | $12,000 |

Factors Affecting Cost

Several factors can affect the cost of these medications, including:

* Insurance coverage: Patients with insurance coverage may have a lower out-of-pocket cost than those without coverage.
* Dosage: The dosage of the medication can affect the cost. For example, Keytruda is available in a 100mg vial, while Opdivo is available in a 10mg vial.
* Administration method: The method of administration can also affect the cost. For example, Keytruda is administered intravenously, while Opdivo is administered subcutaneously.

Conclusion

In conclusion, the cost of Keytruda is slightly higher than its competitors. However, it's essential to note that the actual cost to patients and healthcare providers can vary depending on several factors. Patients and healthcare providers should consult with their insurance provider and the pharmaceutical company to determine the actual cost of these medications.

Key Takeaways

* Keytruda is a PD-1 inhibitor that has been approved for the treatment of various types of cancer.
* The WAC of Keytruda is around $12,500 per month.
* Opdivo, Yervoy, and Tecentriq are similar treatments that have been approved for the treatment of various types of cancer.
* The cost of these medications can vary depending on several factors, including insurance coverage, dosage, and administration method.

Frequently Asked Questions

Q: What is the difference between Keytruda and Opdivo?
A: Keytruda is a PD-1 inhibitor that works by blocking the interaction between PD-1 and PD-L1, while Opdivo is a PD-1 inhibitor that works by stimulating the immune system to attack cancer cells.

Q: Is Keytruda more effective than Opdivo?
A: Both Keytruda and Opdivo have been shown to be effective in treating various types of cancer. The choice between the two medications will depend on the patient's specific diagnosis and treatment plan.

Q: Can I get financial assistance for Keytruda?
A: Yes, Merck & Co. offers financial assistance programs for patients who are unable to afford Keytruda. Patients should consult with their healthcare provider and the pharmaceutical company to determine eligibility.

Q: Is Keytruda available in generic form?
A: No, Keytruda is not available in generic form. However, the patent for Keytruda is set to expire in 2028, which may lead to the development of generic versions of the medication.

Q: Can I take Keytruda with other medications?
A: Yes, Keytruda can be taken with other medications, including chemotherapy and immunotherapy medications. Patients should consult with their healthcare provider to determine the best treatment plan.

Sources

1. Merck & Co. (2022). Keytruda (pembrolizumab) Prescribing Information.
2. Bristol-Myers Squibb (2022). Opdivo (nivolumab) Prescribing Information.
3. Genentech (2022). Tecentriq (atezolizumab) Prescribing Information.
4. DrugPatentWatch.com (2022). Pembrolizumab (Keytruda) Patent Expiration.
5. National Cancer Institute (2022). Immunotherapy for Cancer Treatment.